Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Active | |||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
Keytruda | pembrolizumab | Biliary tract carcinoma | Active | |||
Qulipta | atogepant | Migraine, prevention | Active | |||
Tagrisso | osimertinib | Non-small cell lung cancer | Active | |||
Vraylar | cariprazine | Schizophrenia | Active | |||
N/A | Pembrolizumab | Melanoma (Skin) | Active | |||
N/A | Nivolumab and Ipilimumab | Melanoma (Skin) | Active | |||
Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
Erbitux | Cetuximab | Cancelled |